The Cardiac Biomarkers Market is expected to reach a value of USD 13,370 million in 2023. With a linear growth pattern, it is predicted to reach a value of USD 38,000 million by 2033, growing at a compound annual growth rate of 11% between 2024 - 2033.
Tests for cardiac biomarkers are carried out when a patient experiences chest pain. Cardiovascular disease screening tests use troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP) as cardiac biomarkers. The cardiac biomarkers that are frequently used as an integrated diagnostic approach for cardiovascular diseases include myoglobin, brain natriuretic peptide (BNPs), ischemia modified albumin (IMA), cardiac muscle creatine kinase (CK-MB), troponin I and T, and myoglobin. This creates a more favorable environment for the overall growth of the cardiac biomarker market.
Protein molecules known as cardiac biomarkers are discharged into the bloodstream during heart attack or severe cardiac strain. These indicators serve as possible diagnostic tools for a number of cardiovascular illnesses (CVD), including congestive heart failure, myocardial infarction, acute coronary syndrome, and cardiac ischemia. Cardiac biomarker testing are the test used to assess the risk and health of patients associated with such diseases.
Sample Report Available at Your Request: https://wemarketresearch.com/sample-request/cardiac-biomarker-market/1306
One major trend that is becoming more and more popular in the cardiac biomarker market is technological improvement.To maintain their market position, companies in the cardiac biomarker industry are using innovative technologies.
Market Dynamics
Numerous factors, including the growing prevalence of cardiovascular disorders, rising R&D spending, and advancements in cardiac biomarker technology, are driving the cardiac biomarker market. For example, data from the British Heart Foundation released in January 2022 stated that, worldwide in 2021, ischemic heart disease, peripheral arterial (vascular) disease, stroke, and atrial fibrillation accounted for 110 million, 100 million, and 60 million of all heart conditions affected.
Cardiac Biomarker Market Segmental Analysis –
Country Scope
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria
Cardiac Biomarker Market Competitive Outlook
F. Hoffmann-La Roche AG, Abbott, Siemens AG, Creative Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific Inc., bioMérieux SA Others
By Type
Troponin
CK-MB
Myoglobin
BNP and NT-proBNP
By Application
Acute Coronary Syndrome
Myocardial Infarction
By End-User
Hospital
speciality Clinics
Click here for a more detailed explanation: https://wemarketresearch.com/purchase/cardiac-biomarker-market/1306?license=single
Frequently Asked Questions
1. Which are the top companies operating within the market?
2. Which region dominates the Cardiac Biomarker market?
3. What is the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?
4. What is the market size of Cardiac Biomarker market in 2022?
5. What is PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?
About We Market Research:
WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.
Our strategic market analysis and capability to comprehend deep cultural, conceptual and social aspects of various tangled markets has helped us make a mark for ourselves in the industry. WE MARKET RESEARCH is a frontrunner in helping numerous companies; both regional and international to successfully achieve their business goals based on our in-depth market analysis. Moreover, we are also capable of devising market strategies that ensure guaranteed customer bases for our clients.
Contact Us:
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
Related Articles:
Transparency Market Research (TMR) has published a new report titled, ‘Cardiac Biomarker Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.
According to the report, the global cardiac biomarker diagnostic kits market was valued at around US$ 2.2 Bn in 2018 and is projected to grow at a CAGR of 5.2% from 2019 to 2027Request Brochure –https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=62931Overview Cardiac biomarkers are also called cardiac markers.
In a condition when the heart is damaged or stressed, cardiac biomarkers (endogenous substances including enzymes, hormones, and proteins) are released into the blood.Generally, cardiac markers are used to diagnose heart attack and acute coronary syndrome (ACS) or conditions associated with insufficient blood flow to the heart.
These markers are also utilized in the diagnosis and risk stratification of patients with chest pain.Among cardiac biomarker tests, troponin is the biomarker test of choice for detecting heart damage.
Troponin is elevated within a few hours of heart damage and stays elevated up to two weeks.There are other established biomarkers, such as myoglobin (test used along with troponin for early detection of heart attack) and creatinine kinase isoenzymes (also called cardiac enzyme, which is linked with injury of heart muscle and detection of a second heart attack anticipated shortly after the first)Request COVID Analysis on Cardiac Biomarker Diagnostic Kits Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=62931Rise in prevalence of cardiovascular diseases across the world to Drive MarketGrowing prevalence of cardiovascular diseases across the world is the major driver for the growth of global cardiac biomarker diagnostic kits market.For instance, the American Heart Association estimated that 5 millionadults had cardiovascular diseases between 2013 and 2016Advancements in novel technologies and increasing government funding for cardiovascular disease treatment are some of the major factors responsible for the growth of global cardiac biomarker diagnostic kits marketMoreover, early detection to track the heart condition and integration of cardiology & IT are also some of the major factors fuelling the growth of global cardiac biomarker diagnostic kits marketRequest Customization on Cardiac Biomarker Diagnostic Kits Market Report –https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=62931Troponin Test Kits Segment to Dominate MarketBased on product, the global cardiac biomarker diagnostic kits market has been segmented into troponin test kits, CK-MB test kits, myoglobin test kits, BNP test kits, C-reactive Protein (hsCRP), and other biomarkersTroponin test kits segment is accounted for major market share in global cardiac biomarker diagnostic kits market in 2018Growth of troponin test kits segment can be ascribed to its prodigious specificity and ability to accurately detect the cardiac events of acute coronary syndrome (ACS).Cardiac Heart Failure – Promising Application SegmentIn terms of application, the global cardiac biomarker diagnostic kits market has been divided into angina pectoris, myocardial infarction (MI), cardiac heart failure, and othersAngina pectoris dominated the global market in 2018 and is projected to dominate by the end of 2027 due to high incidence rate of angina pectoris across the globeCardiac heart failure is more lucrative segment during the forecast period which is growing with a higher CAGR during the same period of 2019-2027 owing to rise in number of patient cases for cardiac heart failure across the worldPont-of-care testing Segment– Higher Growth RateOn the basis of testing, the global cardiac biomarker diagnostic kits market has been bifurcated into laboratory testing, and point-of-care testingPoint-of-care testing is more promising segment which is expected to grow with higher CAGR during the forecast period.Easy accessibility of point-of-care testing, increase in preference for point-of-care testing, and new kits & assays being offered by market players for rapid tests are expected to drive the point-of-care testing segment during the forecast period.Diagnostic Laboratory End-user Segment- Major Market ShareBased on end-user, the global cardiac biomarker diagnostic kits market has been segmented into hospitals, clinics, and diagnostic laboratoryDiagnostic laboratory segment dominated the global cardiac biomarker diagnostic kits market in 2018 due to rise in hospital admissions for dental procedures, favorable reimbursement scenario, and increase in number of advanced diagnostic laboratories in the last decade which has led to a higher number of diagnostic tests being performed at these settingsBuy Cardiac Biomarker Diagnostic Kits Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=62931=SNorth America to Dominate Global MarketIn terms of region, the global cardiac biomarker diagnostic kits market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.North America accounted for major share of the global cardiac biomarker diagnostic kits market in 2018 due to higher cardiovascular disease patient population, significant average selling price of analyzers, rise in demand for technologically advanced diagnostic instruments with enhanced specificity and precision among cardiologist, and favorable coverage as per the Clinical Laboratory Improvement Amendments for in-vitro diagnostic procedures in the regionFor instance, an article published in the Medscape states that more than8 millionpeople in the U.S. experience symptoms of angina, annually, and more than 500,000 cases are registered every yearThe cardiac biomarker diagnostic kits market in Asia Pacific is anticipated to expand at a high CAGR from 2019 to 2027.
This can be ascribed to growing aging population, developing health care infrastructure, large patient population, increase in funding and investment toward the development of cardiac analyzers, and surge in focus of both international and domestic players in the region.Competitive LandscapeThe global cardiac biomarker diagnostic kits market is consolidated as few players hold major market share in global market.
